SHEL.UK

3,272

-1.3%↓

BP

563.9

-2.42%↓

REN

31.12

+1.7%↑

SDR

580

+0.17%↑

PSON

1,103

+2.22%↑

SHEL.UK

3,272

-1.3%↓

BP

563.9

-2.42%↓

REN

31.12

+1.7%↑

SDR

580

+0.17%↑

PSON

1,103

+2.22%↑

SHEL.UK

3,272

-1.3%↓

BP

563.9

-2.42%↓

REN

31.12

+1.7%↑

SDR

580

+0.17%↑

PSON

1,103

+2.22%↑

SHEL.UK

3,272

-1.3%↓

BP

563.9

-2.42%↓

REN

31.12

+1.7%↑

SDR

580

+0.17%↑

PSON

1,103

+2.22%↑

SHEL.UK

3,272

-1.3%↓

BP

563.9

-2.42%↓

REN

31.12

+1.7%↑

SDR

580

+0.17%↑

PSON

1,103

+2.22%↑

Search

Smith & Nephew PLC

Open

1,142.5 0.93

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1129.5

Max

1146

Belangrijke statistieken

By Trading Economics

Inkomsten

47M

342M

Verkoop

318M

3.3B

K/W

Sectorgemiddelde

22.302

80.87

EPS

0.429

Dividendrendement

3.38

Winstmarge

10.36

Werknemers

16,988

EBITDA

162M

886M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+28.97% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.38%

3.38%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.1B

10B

Vorige openingsprijs

1141.57

Vorige sluitingsprijs

1142.5

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 apr 2026, 23:08 UTC

Winsten

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 23:07 UTC

Winsten

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:20 UTC

Winsten

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr 2026, 23:47 UTC

Marktinformatie

Global Equities Roundup: Market Talk

30 apr 2026, 23:47 UTC

Marktinformatie

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr 2026, 23:27 UTC

Marktinformatie

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr 2026, 23:22 UTC

Winsten

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr 2026, 23:20 UTC

Marktinformatie

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr 2026, 22:52 UTC

Winsten

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:33 UTC

Winsten

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr 2026, 22:32 UTC

Winsten

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr 2026, 22:32 UTC

Winsten

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr 2026, 22:11 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 apr 2026, 22:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

30 apr 2026, 22:11 UTC

Marktinformatie

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr 2026, 22:05 UTC

Winsten

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 21:57 UTC

Winsten

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr 2026, 21:56 UTC

Winsten

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr 2026, 21:56 UTC

Winsten

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr 2026, 21:55 UTC

Winsten

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr 2026, 21:54 UTC

Winsten

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr 2026, 21:54 UTC

Winsten

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr 2026, 21:53 UTC

Winsten

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr 2026, 21:49 UTC

Winsten

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr 2026, 21:49 UTC

Winsten

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

28.97% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,460.57 GBX  28.97%

Hoogste 1,700 GBX

Laagste 1,300 GBX

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

3

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat